Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional

GW873140 In Combination With Kaletra In HIV Infected Subjects

ClinicalTrials.gov ID: NCT00102778

Public ClinicalTrials.gov record NCT00102778. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jun 25, 2026, 2:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase IIb, 96 Week, Randomized, Open-label Multicenter, Parallel Group, Repeat Dose Study to Evaluate the Safety, Tolerability, PK and Antiviral Effect of Different Doses and Regimens of GW873140 in Combination With Kaletra (Lopinavir and Ritonavir) in HIV-1 Infected Antiretroviral Therapy naïve Subjects

Study identification

NCT ID
NCT00102778
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
ViiV Healthcare
Industry
Enrollment
175 participants

Conditions and interventions

Interventions

  • GW873140 Drug
  • Kaletra (lopinavir/ritonavir) Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2004
Primary completion
Aug 31, 2007
Completion
Aug 31, 2007
Last update posted
May 29, 2017

2004 – 2007

United States locations

U.S. sites
32
U.S. states
16
U.S. cities
26
Facility City State ZIP Site status
GSK Investigational Site Phoenix Arizona 85006
GSK Investigational Site Tucson Arizona 85745
GSK Investigational Site Fountain Valley California 92708
GSK Investigational Site Long Beach California 90813
GSK Investigational Site Los Angeles California 90027
GSK Investigational Site Los Angeles California 90069
GSK Investigational Site San Francisco California 94115-1931
GSK Investigational Site Denver Colorado 80220
GSK Investigational Site Washington D.C. District of Columbia 20007
GSK Investigational Site Washington D.C. District of Columbia 20036
GSK Investigational Site Bradenton Florida 34205
GSK Investigational Site Fort Lauderdale Florida 33306
GSK Investigational Site Fort Lauderdale Florida 33308
GSK Investigational Site Fort Myers Florida 33901
GSK Investigational Site Orlando Florida 32804
GSK Investigational Site Tampa Florida 33614
GSK Investigational Site West Palm Beach Florida 33408
GSK Investigational Site Atlanta Georgia 30308
GSK Investigational Site Atlanta Georgia 30339
GSK Investigational Site Chicago Illinois 60613
GSK Investigational Site Chicago Illinois 60657
GSK Investigational Site New Orleans Louisiana 70115
GSK Investigational Site New Orleans Louisiana 70127-0800
GSK Investigational Site Jackson Mississippi 39202
GSK Investigational Site Santa Fe New Mexico 87505
GSK Investigational Site New York New York 10014
GSK Investigational Site Charlotte North Carolina 28209
GSK Investigational Site Portland Oregon 97209
GSK Investigational Site Allentown Pennsylvania 18103
GSK Investigational Site Philadelphia Pennsylvania 19102
GSK Investigational Site Houston Texas 77027
GSK Investigational Site Hampton Virginia 23666

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 38 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00102778, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 29, 2017 · Synced Jun 25, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00102778 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →